A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of IP-001 as Adjuvant Therapy in Participants With Hepatocellular Carcinoma After Complete Radiological Response After Surgical Resection and Local Ablation or Local Ablation Alone
Latest Information Update: 21 Aug 2024
Price :
$35 *
At a glance
- Drugs InCVAX N dihydro galacto chitosan (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 19 Aug 2024 Status changed from not yet recruiting to recruiting.
- 06 Aug 2024 New trial record